Royalty Report: Drugs, Cancer, Drug Discovery – Collection: 239157

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Cancer
  • Drug Discovery
  • Proteins
  • Disease
  • Therapeutic
  • Assay
  • Diagnostic
  • Diabetes Treatment
  • DNA

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 239157

License Grant
Licensor grants to the Israeli Licensee the worldwide right and exclusive license to make, have made, use, lease and sell the Licensed Products and to practice the Licensed Processes for the Field of Use to the end of the term for which the Patent Rights are granted, unless sooner terminated as provided in this Agreement.
License Property
The patents are for Short peptides which selectively modulate the activity of protein tyrosine kinases, and, Short Peptides which selectively modulate the activity of serine/threonine kinases.

KinAce platform represents one of the first practical uses of the genomics database to systematically generate drug candidates that target protein kinases. We use computer programs to analyze genomic data that then enables us to create compounds that aim to regulate kinases.  Protein kinases play a key role in the way cells communicate. When protein kinases give an inappropriate signal, the result is often a disease or other unwanted medical condition. Our KinAce platform uses a proprietary algorithm to identify unique regulatory regions within each kinase.

Field of Use
The Field of Use shall mean the diagnosis, prevention or treatment of any and all diseases or conditions in humans or animals.

IPSCIO Record ID: 310414

License Grant
The Company was assigned an Option by a Third Party and would like to exercise its right under the Option Agreement to take an Exclusive License to the technology covered in the Option Agreement

University grants an exclusive right and license to practice under the Licensed Patents and Licensed Technology to make, have made, develop, promote, market, import, export, distribute, offer for sale and sell and otherwise use the Licensed Products in the Field of Use within the Licensed Territory during the Term of this Agreement, with rights to Sublicense any and all of such rights to Sublicensees in accordance with the terms of this Agreement.

License Property
Licensor is a research university,  These products are related to patents filed by University directed to methods using the active ingredient in the anti-cancer agent Imatinib, as an anti-infective. These compounds were designed to inhibit c-Abl in patients for a therapeutic purpose. These patents formed the starting point for Licensees RAMP drug discovery program.

The Patents are
Compositions and Methods of Use of Tyrosine Kinase Inhibitors to Treat Infections caused by HIV-1, by Mycobacterium Tuberculosis, and by Polyoma and Related Viruses;  Development of Novel Tyrosine Kinase Inhibitors for Treating Infectious Diseases; Use of Tyrosine Kinase Inhibitors to Treat Mycobacterium Tuberculosis and Related Infections; and, Use of Tyrosine Kinase Inhibitors as Therapeutics for Polyomavirus Infections.

Option Invention shall mean any patentable addition, enhancement, modification, development, alteration, technical advance to Licensed Patents or Licensed Technology to the extent any such improvement is owned or controlled by University.

These products are related to patents filed by Licensor directed to methods using the active ingredient in the anti-cancer agent Imatinib, as an anti-infective.

Field of Use
The Field of Use shall include the prevention, diagnosis, treatment or control of human and animal infectious diseases or related conditions other than Tuberculosis.

The patent rights related to the application of Imatinib or a series of novel analogs for the treatment of infections caused by both viruses and bacteria that utilize c-Abl protein kinase to reproduce in human hosts.

This License grants is related to the application of Imatinib or a series of novel analogs for the treatment of infections caused by both viruses and bacteria that utilize c-Abl protein kinase to reproduce in human hosts.

Licensee is a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Disease, or PD, and related disorders that arise inside and outside of the brain.

IPSCIO Record ID: 308734

License Grant
University hereby grants to Licensee and Licensee hereby accepts from University the License.  License shall mean the exclusive worldwide license to practice the Research Technology (as hereinafter defined) for the research, development, manufacture, use and sale of Licensee Products.
License Property
The University has made certain inventions (the Pre-Existing Inventions) with respect to Receptors used in the products.

Patent Application US Serial # 07/551,270 -Novel Receptor-Type Phosphotyrosinc Phosi1hatases
Patent Application US Serial # 07/654,188 – Novel Rcccptor-lype Phospholyrosine PhosEltatases

Research Technology shall mean all University Patents and University Know-How.

Licensee Product shall mean any product for the diagnosis, treatment or prevention of human disease which contains or comprises
              (i)   any Receptor (as hereinafter defined); and/or (ii)  any substance which activates or prevents activation or otherwise modulates activation of a Receptor; and/or (iii) any substance which induces, prevents or otherwise modulates intracellular activity of either the activated or resting Receptor and/or (iv)  any substance otherwise  physically interacts with a Receptor and/or (v)  DNA or RNA encoding any of said substances, including probes, vectors or cells modified to contain such DNA or RNA; provided that an Investigational New Drug (IND) application is filed for such Licensee Product within 4 years from the end of the Research Period.  Licensee Product shall not include any product that is licensed by Licensee from a third party other than MPG,  provided that such product  does not act by activating, preventing activation, or otherwise modulating a Validated Target.

MPG shall mean Max-Planck-1 Institut fur Biochemie, Abteilung Molekularbiologie (Director Prof. Dr. Axel Ullrich), located in Am Klopferspitz 18a, W-8003 Martinsreid, an institute of the Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., located in Residenzstrasse 1a, W-8000 Munchen 2, or any scientist affiliated with Max-Planck-1 Institut fur Biochemie, and/or Garching Intrumente Gesellschaft zur industriellen Nutzung von Forschungsergebnissen m.b.h. located in Koniginstrabe 19, W-8000 Munchen 22.

University Patents shall mean Universitys share in all United States and foreign patents and patent applications, and any divisions, continuations, in whole or in part, reissues, renewals and extensions thereof, and pending applications therefor (x) which claim Pre-Existing Inventions and which are identified on Appendix I hereto; or (y) which claim  inventions that are made, in whole or in part, by students or employees of University (including the University Scientist) during the term and in the course of the University Research Project (as hereinafter defined). For the avoidance of doubt, University Patents shall  include any such inventions that are made during the term and in the course of the University Research Project, whether funded by Licensee or by United States government agencies under Section 4( c) hereof.

University Know-How shall mean the Pre-Existing Inventions and any information and materials (including, but not limited to, pharmaceutical, chemical, biological and biochemical products, information, trade secrets, know-how, technical and non-technical data, materials, methods and processes and any drawings, plans, diagrams,  specifications and/or other documents containing such information) discovered, developed or acquired by or on behalf of students or employees of University (including The University Scientist) during the term and in the course of the University Research Project (as hereinafter defined).  For the avoidance of doubt, University Know-How shall include any of the foregoing that are developed during the term and in the course of the University Research Project whether funded by Licensee or by United States government agencies wider Section 4( c) hereof.

Receptor shall mean
(i) receptor tyrosine kinases, intracellular tyrosine kinases, or receptors that directly or indirectly activate non-receptor tyrosine kinases; and/or (ii) receptor serine/threonine kinases, intracellular serine/threonine kinases, or receptors that directly or indirectly activate serine/threonine kinases and/or (iii) receptor tyrosine phosphatases, intracellular tyrosine phosphatases, or receptors that directly or indirectly activate tyrosine phosphatases; and/or (iv) molecules that regulate the signaling of the above receptors.

Field of Use
The field of use is for human diseases relating to the diagnosis, treatment or prevention of these human diseases primarily cancer and diabetes.

The Licensees objective is to discover and develop new classes of small molecule drugs which interact in a specific manner with different members of the tyrosine kinase, serine-threonine kinase and tyrosine phosphatase families of signal transduction pathways.  These pathways are involved in a number of human diseases including cancer and diabetes as well as disorders of the bodys immune defenses and neurological systems.

IPSCIO Record ID: 257478

License Grant
Licensor grants the Swiss Licensee an exclusive worldwide license under Licensor Technology to the extent useful to permit Licensee to carry out its rights and obligations set forth in this Agreement and to develop, manufacture, have manufactured, market. use, sell and import for sale, as provided herein, Bulk Drug Substance, Drug Product Candidates and Drug Products worldwide.

This agreement includes a non-exclusive grant back to Licensor from Licensee.

License Property
Licensor has undertaken a broad drug discovery program with the objective of designing novel, small-molecule compounds targeting the kinase protein superfamily.

Technology shall mean Licensee Kinase Technology and Licensor Kinase Technology.

Kinase Technology shall mean all data, technical information, know-how, experience, inventions, whether or not patented, trade secrets, processes and methods discovered, developed or applied,with the consent of its owner, and Controlled by either party or its Affiliates, in connection with performance by either party under the Research Program, or in connection with the conduct of a Development Program under the License Agreement prior to termination of the Research Program, that relate to the research, development, utilization, manufacture or use of Compounds, Development Candidates, Drug Candidates, Drug Product Candidates or Drug Products, other than any such technology which is exclusive to Excluded Kinases; provided, however, that the term Kinase Technology shall not apply to Licensors general drug design technology whether in hardware or software form, tangible or intangible.

Field of Use
Field shall mean the treatment or prevention of conditions or diseases in humans, principally by affecting a Kinase other than an Excluded Kinase.

IPSCIO Record ID: 243433

License Grant
For the Licensed IP Rights, the Italian Licensor grants an exclusive license under the Licensed IP Rights to conduct research and to develop, make, have made, use, offer for sale, sell and import Products in the Territory for use in the Field, and, Licensor grants a non-exclusive license under any patent, know-how or other intellectual property rights Controlled by Licensor to research and to develop, make, have made, use, offer for sale, sell and import any diagnostic product for one or more of the Exclusive Targets.
License Property
Product(s) shall mean any product that incorporates one or both of the APls and if made, used, sold, offered for sale or imported absent the license granted hereunder would infringe a Valid Claim, or that otherwise uses or incorporates the Licensor Know-How.

The patent is for Substituted Indazole Derivatives Active as Kinase Inhibitors.

RXDX-103 is an inhibitor of the cell division cycle 7-related (Cdc7) protein kinase, and RXDX-104 is a program to identify a highly selective inhibitor of the rearranged during transfection (RET) tyrosine kinase. Each of these programs is in preclinical development for the potential treatment of multiple cancers.

Loss of cell cycle control is a hallmark of cancer, and interfering with the DNA replication process is a proven strategy for cancer therapy. Currently available chemotherapies, such as anti-metabolites, topoisomerase inhibitors, and crosslinking and intercalating agents, classically take a broad-based approach to inhibiting the elongation step of DNA replication. This strategy has led to successful treatment outcomes, but off-target effects can lead to dose-limiting toxicity. Cdc7 is a serine/threonine protein kinase essential for the initiation step of DNA replication during the synthesis (S) phase.

Field of Use
The Field shall mean all fields of use, including without limitation the diagnosis, prevention or treatment of any disease, state or condition in humans or other animals.

Licensee has capabilities in the development of oncology products.

IPSCIO Record ID: 240480

License Grant
The University grants to Licensee a world-wide, non-transferable license under its rights in and to the Patent Rights, only in the Field of Use, to make, have made, use, sell, offer to sell and import Patent Products, and to use and practice the Licensed Methods and Patent Rights, including for purposes of identifying, creating, discovering, developing and commercializing Identified Products, in the Field of Use.

The University also grants to Licensee the right to sublicense to third parties.

License Property
Therapeutic Licensed Product means a Licensed Product that is used to prevent, treat or cure one or more diseases and/or conditions of human beings or animals.

Diagnostic Licensed Product means a Licensed Product that is used as a human or veterinary diagnostic and/or prognostic.

Identified Product means a Product that has prophylactic, therapeutic, diagnostic or prognostic value and is identified, created, discovered or developed as a result of practicing the Licensed Method, use of Patent Products, or use or practicing of any Product, process or method anywhere in the world covered by a Valid Claim within the Patent Rights in any one country.

Certain inventions, generally characterized as Nucleic Acids Encoding Neural Axon Outgrowth Modulators, Netrins, Netrin Receptors, Semaphorin Receptors, Human Netrin~1, Promoters of Neural Regeneration and Compositions for Promoting Nerve Regeneration.

Patents include small molecule, Ligands and Receptors.

Field of Use
Field of Use means any and all uses, including for or relating to human or veterinary prophylaxes; therapeutics, diagnostics and prognostics, including without limitation use in assaying or screening for therapeutic, diagnostic and prognostic targets, validation of therapeutic, diagnostic and prognostic targets, and use for drug discovery purposes such as the identification of new chemical entities, but specifically excluding Research Reagent Use.

IPSCIO Record ID: 289175

License Grant
For the Commercial License to Clinical Candidates and Corresponding Products, Licensor grant an exclusive license, with the right to grant and authorize sublicenses through multiple tiers, under the Licensor Technology and Licensors interest in the applicable Collaboration Technology, to make, have made, use, offer for sale, sell, import, export and otherwise exploit Active Compounds, Clinical Candidates, Lead Compounds and Products for use in the Field and in the Territory.
License Property
The Parties have each identified multiple oncology kinase targets that have the potential to be used as the basis for drug discovery programs.

Active Compound shall mean a Compound that modulates a Target, the mechanism of which is a binding interaction with a Target, having a level of activity against a Target, expressed as an IC50, that is – less than forty (40) nanomolar- as measured in the applicable in vitro biochemical assay set forth in the Discovery Plan; and a Compound that modulates at least two of the following receptors TrkA, TrkB or TrkC, the mechanism of which is a binding interaction with the applicable Trk receptor, having a level of activity against the applicable Trk receptor, expressed as an ICso, that is less than forty (40) nanomolar as measured in the applicable in vitro biochemical assay set forth in the Discovery Plan.

Clinical Candidate shall mean, with respect to each Target or Trk, any Active Compound that meets the Clinical Candidate Criteria set forth in the Discovery Plan.

Compound shall mean any one or more chemical entity(ies) made and tested against Trk in the course of Licensors pan-Trk program prior to the Effective Date, or synthesized by Licensor in the course of performing or in connection with the Discovery Program, in each case together with any salt, hydrate, solvate, clathrate, polymorph or isomer thereof.

Product shall mean any pharmaceutical product incorporating as an active ingredient an Active Compound.

Trk shall mean the Trk family of receptors TrkA, Tr kB and TrkC.
—  TrkA shall mean the protein known as UniProtKB/Swiss-Prot # P04629.
—  TrkB shall mean the protein known as UniProtKB/Swiss-Prot # Q16620.
—  TrkC shall mean the protein known as UniProtKB/Swiss-Prot # Q16288.

The Targets are
—  The protein family commonly known as Firbroblast Growth Factor Receptors (FGFR),
—  The protein commonly known as [p70S6 Kinase], identified with the following SwissProt entries
a) Ribosomal protein S6 kinase beta-1 (P23443)
b) Ribosomal rotein S6 kinase beta-2 (Q9UBS0]—  The protein commonly known as Telomerase reverse transcriptase, identified with the following SwissProt entries
a) Telomerase reverse transcriptase (014746)
b) Telomerase protein component 1 (Q99973)

Field of Use
The development and commercialization agreement pertain to certain Array-invented compounds targeted at a specified novel oncogenic activating mutation.

Licensee possesses pharmaceutical research, development and commercialization capabilities, as well as proprietary technology in the field of cancer treatment.

IPSCIO Record ID: 233462

License Grant
Licensor grants to Licensee
(a) an exclusive, worldwide license, under Licensor Field Patent Rights and Licensor Field Know-How, to make, have made, use, and have used Candidate Genes and Validated Targets within Oncology; such license shall include the right to grant sublicenses on prior notice to Licensor;
(b) an exclusive, worldwide license, under Licensor Field Patent Rights and Licensor Field Know-How to make, have made, import, use, have used, offer to sell and sell Products; such license shall include the right to grant sublicenses on prior notice to Licensor;
(c) an option to obtain exclusive licenses to Non-Program Field Projects;
(d) a right to either negotiate for rights to collaborate on Gene Therapy Drugs, which embody or are discovered or developed using Licensor Field Patent Rights or Licensor Field Know-How, or a co-exclusive right to make, have made, import, use, have used, offer to sell and sell Gene Therapy Drugs, which embody or are discovered or developed using Licensor Field Patent Rights or Licensor Field Know-How;
(e) an option to co-develop and/or co-promote certain Diagnostic Products, for use in the Field and the area of Oncology, which embody or are discovered or developed using Licensor Field Patent Rights or
Licensor Field Know-How; and
(f) a co-exclusive with Licensor, worldwide license, under Licensor Field Patent Rights and Licensor Field Know-How, to make, have made, use, and have used Program Genes Outside of the Field and to make, have made, use, and have used Candidate Genes and Validated Targets outside of Oncology; such license shall include the right to grant sublicenses on prior written notice to Licensor.
License Property
Gene Therapy Drug means any drug or drug candidate, excluding an Antisense Drug, which consists of nucleic acid or a functional analog, derivative or homologue thereof and which, upon delivery by any means, provides a gene product encoded therein which is expressed.

Modified Drug means a compound in the Field which, other than through the use of Licensor Field Know-How or Licensor Field Patent Rights, prior to or outside of the Program, was identified by Licensee to have pharmacological properties of relevance -to its development as a therapeutic product in the Field, and was modified through the use of Licensor Field Know How or Licensor Field Patent Rights to improve its therapeutic properties at any time during the term of the Program or the Licensee Development Program. Modified Drug does not include any Candidate Protein Drug, Peptido Mimetic, Analog Protein Drug, Small Molecule Drug, Gene Therapy Drug or Antisense Drug.

Candidate Protein Drug means a Protein encoded by a Candidate Gene or other Protein, the identification of which other Protein was based upon the identification of a Candidate Gene, and which, in either case, is potentially suitable for development into a therapeutic product.

Analog Protein Drug means a protein or polypeptide which has been modified through a change in its primary structure resulting in a functionally significant change (such as a change in its pharmacokinetic or pharmacodynamic properties) to allow it to become a therapeutic Product demonstrating relevant In Vitro and In Vivo activity. For purposes of this definition, a polypeptide constituting the pharmacologically active fragment of a protein, that has not been modified through a change in its primary structure resulting in a functionally significant change, shall not be considered an Analog Protein Drug.

Peptido Mimetic Drug means a synthetic organic molecule which is a mimetic of, or is designed or developed using medicinal, SAR or combinatorial chemistry techniques to incorporate, key structural features of a Candidate Protein Drug and which is a therapeutic product.

Small Molecule Drug means a small molecule therapeutic product within the Field originating from a screen using a Validated Target, other than a Candidate Protein Drug, an Analog Protein Drug, a Peptido Mimetic Drug, a Modified Drug, a Gene Therapy Drug or an Antisense Drug.

Field of Use
Field means the application in Oncology of
(a) All genes located at chromosome 8p22, including but not limited to loss of prostate cancer hormone-sensitivity, and prostate cancer metastasis to bone;
(b) Mechanisms of drug resistance including but not limited to the association with drug transporters such as P-glycoprotein and MRP, and the mechanism of action of factors that mediate cell death of drug resistant cells or tissues, including but not limited to apoptosis;
(c) Mechanisms of prostatic proliferative conditions including but not limited to the discovery of novel genes implicated in the susceptibility, progression and metastasis of prostate cancer, analysis of prostatic cells and variants of these cells, and malignant tissues;
(d) All cell cycle control mechanisms including but not limited to inhibition of cyclin DI/CDK4 kinase activity; and
(e) All Ras signal transduction mechanisms including but not limited to the inhibition of the Ki-ras pathway, Ras/GTP interaction, Ras/Raf interaction, Raf kinase activity, and Ras/FTase interaction.

Outside of the Field means all human medical indications other than those in the Field and all animal medical indications.

IPSCIO Record ID: 328341

License Grant
Licensor grants
a. an exclusive, worldwide license in the Fields of Use to practice Licensor Technical Information to develop, identify, make, use and sell Product(s); and
b. an exclusive, worldwide license to practice Licensor Technical Information to develop, make, use, license and sell Assays that utilize or incorporate Licensor Technical Information.
License Property
Licensor developed various technologies relating to signal transduction within cells, and Licensor owns all rights, title and interest in and to such technologies, including related patents, patent applications and unpatented technology relating to mammalian cell and/or enzyme- based assays useful in identifying compounds that regulate cellular transduction pathways.

Products shall mean any compound, formulation or composition whose utility is identified using an Assay.

Assay shall mean one or more mammalian cell and/or enzyme-based assays relating to the regulation of cellular transduction pathways, including G protein-coupled and/or tyrosine kinase-coupled receptor signal transduction pathways, which incorporates or utilizes Licensor Technical Information.

The patents include
–  Method and product for regulating cell responsiveness to external signals,
–  Using tyrosine phosphorylation of map kinase and characterization of the components of the map kinase activation pathway as a drug discovery assay system,
–  Product and process for regulating signal transduction pathways, and,
–  Method and product for regulating cell responsiveness to external signals.

Field of Use
The Fields of Use shall mean all agricultural, veterinary and human therapeutic and diagnostic uses for Licensor Technical Information.

Licensee is engaged in the discovery of novel small molecule therapeutics that act on targets in human cell signaling pathways.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.